Abstract
Background: Tinnitus affects approximately 10–15% of adults and remains a significant medical challenge. Given the role of glutamate excitotoxicity in tinnitus pathophysiology, N-methyl-D-aspartate receptor antagonism represents a promising pharmacological target. This study aimed to evaluate the effect of adjunctive memantine, added to betahistine, on tinnitus severity, insomnia, and quality of life among patients with primary tinnitus. Methods: A single‑blind, randomized controlled trial was conducted on 60 patients with primary tinnitus. All participants received conventional treatment with betahistine (8 mg/day) for 90 days. The intervention group additionally received memantine, titrated up to 20 mg/day, while the control group received a placebo. Outcomes were assessed at baseline and three months post-intervention using the Tinnitus Handicap Inventory, Insomnia Severity Index, and Short Form‑36 Health Survey (SF-36). Data analysis was conducted using chi‑square and independent samples t‑tests with statistical significance set at P < 0.05. Results: At the end of follow-up, the intervention group showed a significant shift toward lower tinnitus severity, with 50% reporting mild and 31% slight tinnitus, while the control group showed no improvement, and 60% remained in the severe category. The between‑group difference in the tinnitus severity distribution was statistically significant (P = 0.001). The intervention group demonstrated significantly greater improvements in health-related quality of life across multiple SF-36 domains and a significant reduction in insomnia severity compared with the control group, with between-group results favoring the memantine-plus-betahistine group (P < 0.05). Conclusion: Adding memantine to betahistine may improve tinnitus-related outcomes compared with betahistine alone. Larger double-blind trials are needed to confirm these findings.